Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model,

This article was originally published in The Pink Sheet Daily

Executive Summary

From offices in North Carolina and Hangzhou, the start-up will in-license compounds to sell in China while developing its own candidates.

You may also be interested in...



Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing

A six-year-old start-up founded by Vicuron veterans has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.

Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis

U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.

Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate

U.S.-China hybrid Ascletis is in-licensing rights to Phase II-ready RNA-interference program ALN-VSP from Alnylam with an eye on developing a groundbreaking therapy for an underserved indication that hits especially hard in China.

Related Content

Topics

UsernamePublicRestriction

Register

PS072196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel